# NETTER-2 (NCT03972488)

> Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03972488
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Advanced Accelerator Applications
- Conditions: Gastro-enteropancreatic Neuroendocrine Tumor
- Interventions: Lutathera; 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot); 2.5% Lys-Arg sterile amino acid solution; High dose 60 mg octreotide long-acting repeatable
- Enrollment: 226
- Primary outcome: Progression Free Survival (PFS) Per Central Assessment

## Commentary we found

- X threads: 102
- Podcasts: 21
- YouTube: 19

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=netter-2-nct03972488

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03972488", "email": "<work email>"}; the inbox owner confirms by the emailed link.